Engineered immune cells take on tough blood cancers in early trial
NCT ID NCT04892277
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment called IC19/1563 for people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is to find the safest dose and see if the approach is feasible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Brain training before CAR-T may protect memory, study hopes
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Supercharged immune cells take on tough B-Cell cancers in early trial
- Blood cancer transplant study tests safer GVHD prevention
- Stem cell transplant study seeks best way to prevent immune attack